ArticleBiomarker research2016
A robust prognostic gene expression signature for early stage lung adenocarcinoma.
Article in Biomarker research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 29 citations in OpenAlex.
- A multimodal AI biomarker PATH-ORACLE improves prediction of recurrence in stage I lung adenocarcinoma.Immuno-oncology technology · 2026Article
- Analysis of clinicopathological characteristics in postoperative molecular residual disease-positive stage I non-small cell lung cancer patients.Journal of thoracic disease · 2026Article
- DeepCG: A cell graph model for predicting prognosis in lung adenocarcinoma.International journal of cancer · 2024Article
- Improvement of variables interpretability in kernel PCA.BMC bioinformatics · 2023Article
- 5-mRNA-based prognostic signature of survival in lung adenocarcinoma.World journal of clinical oncology · 2023Article
- Integrated Analysis of MATH-Based Subtypes Reveals a Novel Screening Strategy for Early-Stage Lung Adenocarcinoma.Frontiers in cell and developmental biology · 2022Article
- Identification and Validation of 7-lncRNA Signature of Epigenetic Disorders by Comprehensive Epigenetic Analysis.Disease markers · 2022Article
- Systematic profiling of invasion-related gene signature predicts prognostic features of lung adenocarcinoma.Journal of cellular and molecular medicine · 2021Article
- Comprehensive Profiling of Genomic and Transcriptomic Differences between Risk Groups of Lung Adenocarcinoma and Lung Squamous Cell Carcinoma.Journal of personalized medicine · 2021Article
- Integrated analysis of gene expression and DNA methylation datasets identified key genes and a 6-gene prognostic signature for primary lung adenocarcinoma.Genetics and molecular biology · 2021Article
- Analysis of genomic and transcriptomic variations as prognostic signature for lung adenocarcinoma.BMC bioinformatics · 2020Article
- Denoising Autoencoder, A Deep Learning Algorithm, Aids the Identification of A Novel Molecular Signature of Lung Adenocarcinoma.Genomics, proteomics & bioinformatics · 2020Article
- DNA methylation profiling to predict recurrence risk in stage Ι lung adenocarcinoma: Development and validation of a nomogram to clinical management.Journal of cellular and molecular medicine · 2020Article
- A clonal expression biomarker associates with lung cancer mortality.Nature medicine · 2019Article
- Construction of subtype-specific prognostic gene signatures for early-stage non-small cell lung cancer using meta feature selection methods.Oncology letters · 2019Article
- Identification of monotonically differentially expressed genes for non-small cell lung cancer.BMC bioinformatics · 2019Article
- A Pathway-Based Strategy to Identify Biomarkers for Lung Cancer Diagnosis and Prognosis.Evolutionary bioinformatics online · 2019Article
- A 16-gene expression signature to distinguish stage I from stage II lung squamous carcinoma.International journal of molecular medicine · 2018Article
- A novel seven-long non-coding RNA signature predicts survival in early stage lung adenocarcinoma.Oncotarget · 2017Article
- Cancer cells increase endothelial cell tube formation and survival by activating the PI3K/Akt signalling pathway.Journal of experimental & clinical cancer research : CR · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundStage I lung adenocarcinoma is usually not treated with adjuvant chemotherapy; however, around half of these patients do not survive 5 years. Therefore, a reliable prognostic biomarker for early stage patients would be critical to identify those most likely to benefit from early additional treatments. Several studies have searched for gene expression prognostic biomarkers for lung adenocarcinoma, but these have not yielded a widely accepted prognosticator.
resultsWe analyzed gene expression from seven published lung adenocarcinoma cohorts for which we included only stage I and II patients who were not given adjuvant therapy. Seven genes consistently obtained statistical significance in Cox regression for overall survival. The combined signature has a weighted mean hazard ratio of 3.2 in all cohorts and 3.0 (C.I. 1.3-7.4, p < 0.01) in an independent validation cohort and is strongly correlated with previously published signatures of chromosomal instability and cell cycle progression.
conclusionsThe new prognostic signature, if validated prospectively, may enable better stratification and treatment of early stage lung cancer patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.